XML 192 R149.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information - Reconciliation of Adjusted EBITDA to Income (Loss) from Continuing Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended 27 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2021
Reconciliation of Adjusted EBITDA to income from continuing operations            
Income (Loss) from Continuing Operations     $ 452,725 $ 343,096 $ 268,211  
Interest expense, net $ 114,442 $ 104,422 417,961 418,535 419,298  
Provision (Benefit) for Income Taxes 10,080 14,640 176,290 29,609 59,931  
Depreciation and amortization 183,615 165,642 680,422 652,069 658,201  
Acquisition and Integration Costs 15,661 0 12,764 0 13,293  
Restructuring charges 0 39,811 206,426 194,396 48,597 $ 449,419
Intangible impairments     0 23,000 0  
(Gain) loss on disposal/write-down of property, plant and equipment, net (including real estate) (705) (4,451) (172,041) (363,537) (63,824)  
Other (income) expense, net, excluding our share of losses (gains) from our unconsolidated joint ventures(1) 53,515 2,121 (205,746) 133,611 25,720  
Stock-based compensation expense 11,341 10,733 61,001 34,272 36,194  
COVID-19 Costs     0 9,285 0  
Our share of Adjusted EBITDA reconciling items from our unconsolidated joint ventures 1,338 1,016 4,897 1,385 3,388  
Adjusted EBITDA $ 430,994 $ 380,565 $ 1,634,699 1,475,721 $ 1,469,009  
Cost of Sales            
Reconciliation of Adjusted EBITDA to income from continuing operations            
COVID-19 Costs       7,600    
Selling, general and administrative expenses            
Reconciliation of Adjusted EBITDA to income from continuing operations            
COVID-19 Costs       $ 1,600